A study from the University of Houston College of Pharmacy, and published in the Journal of the American Geriatrics Society,
has evaluated the risk of overactive bladder as a side effect
of cholinesterase inhibitor (ChEI) drugs taken for dementia and
Alzheimer disease. The research was based on the dissertation work of
the study’s first author Prajakta Masurkar.
Dementia is a group of symptoms associated with a decline in memory,
reasoning or other thinking skills. Alzheimer disease is the most
common cause of dementia, accounting for 60% to 80% of cases. ChEI drugs,
including donepezil, galantamine and rivastigmine, increase
communication between nerve cells to enhance cognition.
“The study found that the risk of overactive bladder varies
across individual ChEIs,” reports Rajender R Aparasu, Mustafa, and
Sanober Lokhandwala Endowed Professor of Pharmacy and chair, Department
of Pharmaceutical Health Outcomes and Policy. “Using a national cohort
of older adults with dementia, we also found that donepezil was
associated with a 13% increased risk of overactive bladder compared to rivastigmine,
whereas there was no differential risk of overactive bladder with galantamine and
Using Medicare data, the study examined 524,975 adults (aged 65
and older) with dementia who were users of ChEIs (donepezil 80.72%,
rivastigmine 16.41%, galantamine 2.87%). The primary outcome of interest
was overactive bladder diagnosis or prescription of antimuscarinics, drugs, which help
correct overactive bladder, within six months of ChEI initiation.
While some studies have been conducted to evaluate the effects
of all ChEIs and antimuscarinic use, few studies have
been conducted regarding the effects of individual ChEIs on the risk of
overactive bladder. Previous studies have found that the use of ChEIs is associated
with an increased risk of receiving an antimuscarinic drug.
This study opens a new door.
“The findings suggest the need to understand and manage
medication-related morbidity in older adults with dementia,”
Source: News Release
University of Houston
January 6, 2022